title: Autologous bone marrow transplantation for low-grade non-Hodgkin's lymphoma: the European Bone Marrow Transplant Group experience. EBMT Working Party for Lymphoma.
abstract: BACKGROUND
  Influenced by successful results treating intermediate- and high-grade non-Hodgkin's lymphoma (NHL), high-dose therapy followed by autologous bone marrow transplantation (ABMT) is increasingly applied in low-grade NHL. However, the published data are limited.
  
  
  METHODS
  In the European Bone Marrow Transplant Group (EBMT) Registry 92 patients with low-grade NHL treated with ABMT could be identified.
  
  
  RESULTS
  The overall progression-free survival was 52% at 5 years with a median follow-up of 19 months. Patients with a complete remission or responsive disease at ABMT had a better outcome. There was no benefit for patients transplanted with either total body irradiation in the conditioning regimen or a purged autograft.
  
  
  CONCLUSIONS
  Although the median follow-up is short, the data are very promising and warrant a randomized trial analyzing the value of high-dose therapy and purging in low-grade NHL.
authors.forename: H C
authors.initials: HC
authors.lastname: Schouten
authors.forename: P
authors.initials: P
authors.lastname: Colombat
authors.forename: L F
authors.initials: LF
authors.lastname: Verdonck
authors.forename: N C
authors.initials: NC
authors.lastname: Gorin
authors.forename: B
authors.initials: B
authors.lastname: Björkstrand
authors.forename: G
authors.initials: G
authors.lastname: Taghipour
authors.forename: A H
authors.initials: AH
authors.lastname: Goldstone
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D008297:Male; D012074:Remission Induction; D015996:Survival Rate; D016896:Treatment Outcome; D014916:Whole-Body Irradiation